CTI Biopharma Corp expected to post a loss of 21 cents a share - Earnings Preview

CTI Biopharma

04/08/2021 24:08

* CTI Biopharma Corp  CTIC.OQ   CTIC.O  is expected to show a no
change in quarterly revenue when it reports results on August
5. 
​* Refinitiv's mean analyst estimate for CTI Biopharma Corp is
for a loss of 21 cents per share. For the same quarter last
year, the company reported a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for CTI Biopharma
Corp is $6​, about 59.5% above​ its last closing price
of $2.43. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.22       -0.22      -0.23     Missed  -5.7
 Dec. 31 2020              -0.16      -0.20     Missed  -27
 Sep. 30 2020  -0.15       -0.15      -0.15     Met     2.2​
 Jun. 30 2020  -0.12       -0.12      -0.14     Missed  -13.5
 Mar.          -0.13​      -0.13      -0.20     Missed  -53.8​
 31​ 2020​                                              
 Dec. 31 2019  -0.21       -0.22      -0.14     Beat    37.8​
 Sep. 30 2019  -0.23       -0.23      -0.17     Beat    26.1
 Jun. 30 2019  -0.19       -0.19      -0.19     Met     0
 This summary was machine generated August 3 at 23:08 GMT.  All
figures in US dollars unless otherwise stated